Dave Knapp

Trump has about 27 billion reasons why from Eli Lilly this past week as to why they would go ahead and try to help enforce non-legal, at least in their version, at least from their position, non-legal prescribing of compounds.

Trump has about 27 billion reasons why from Eli Lilly this past week as to why they would go ahead and try to help enforce non-legal, at least in their version, at least from their position, non-legal prescribing of compounds.

Trump has about 27 billion reasons why from Eli Lilly this past week as to why they would go ahead and try to help enforce non-legal, at least in their version, at least from their position, non-legal prescribing of compounds.

We know, we know that his best buddy, Elon is, he's openly said that he's taking this epic. And I believe in Jaro even now. And, and, you know, I mean, they're, And from the perspective of this, if you just go and buy the numbers, a good percentage of people within his cabinet have probably been on a GLP-1 also. So I don't think that the benefit of these drugs has escaped them at all.

We know, we know that his best buddy, Elon is, he's openly said that he's taking this epic. And I believe in Jaro even now. And, and, you know, I mean, they're, And from the perspective of this, if you just go and buy the numbers, a good percentage of people within his cabinet have probably been on a GLP-1 also. So I don't think that the benefit of these drugs has escaped them at all.

We know, we know that his best buddy, Elon is, he's openly said that he's taking this epic. And I believe in Jaro even now. And, and, you know, I mean, they're, And from the perspective of this, if you just go and buy the numbers, a good percentage of people within his cabinet have probably been on a GLP-1 also. So I don't think that the benefit of these drugs has escaped them at all.

It'll just be interesting to see what the appetite for the FDA to actually enforce this stuff is.

It'll just be interesting to see what the appetite for the FDA to actually enforce this stuff is.

It'll just be interesting to see what the appetite for the FDA to actually enforce this stuff is.

Yeah. Yeah, I talked a little bit how there's a spectrum, right? So 503Bs have the The 503B pharmacies have the CGMP that is overseen by the FDA. The 503As don't. So 503A pharmacies are overseen by their state pharmacy boards.

Yeah. Yeah, I talked a little bit how there's a spectrum, right? So 503Bs have the The 503B pharmacies have the CGMP that is overseen by the FDA. The 503As don't. So 503A pharmacies are overseen by their state pharmacy boards.

Yeah. Yeah, I talked a little bit how there's a spectrum, right? So 503Bs have the The 503B pharmacies have the CGMP that is overseen by the FDA. The 503As don't. So 503A pharmacies are overseen by their state pharmacy boards.

So when you start, for anyone who's switching to a 503A, a custom formulation or a custom dose in the interim, I would really strongly encourage you to know what pharmacy it's coming from. and then do some research on the state pharmacy boards and make sure that they're a pharmacy in good standing. Because again, there are different checks and balances for 503Bs that don't exist for 503A.

So when you start, for anyone who's switching to a 503A, a custom formulation or a custom dose in the interim, I would really strongly encourage you to know what pharmacy it's coming from. and then do some research on the state pharmacy boards and make sure that they're a pharmacy in good standing. Because again, there are different checks and balances for 503Bs that don't exist for 503A.

So when you start, for anyone who's switching to a 503A, a custom formulation or a custom dose in the interim, I would really strongly encourage you to know what pharmacy it's coming from. and then do some research on the state pharmacy boards and make sure that they're a pharmacy in good standing. Because again, there are different checks and balances for 503Bs that don't exist for 503A.

And then way over here, you have the research grade peptides that are available in the far reaches of the internet without a doctor's prescription that are labeled not for human consumption. So there's a spectrum of safety checks and balances that are built into the non-branded versions. And so when you're talking about that spectrum, they're just simply not all created equal.

And then way over here, you have the research grade peptides that are available in the far reaches of the internet without a doctor's prescription that are labeled not for human consumption. So there's a spectrum of safety checks and balances that are built into the non-branded versions. And so when you're talking about that spectrum, they're just simply not all created equal.

And then way over here, you have the research grade peptides that are available in the far reaches of the internet without a doctor's prescription that are labeled not for human consumption. So there's a spectrum of safety checks and balances that are built into the non-branded versions. And so when you're talking about that spectrum, they're just simply not all created equal.

So the ironic thing about this is the crusade that Lilly and Novo have against compounded versions, their actions are actually leading people to progressively less potentially safe options.

So the ironic thing about this is the crusade that Lilly and Novo have against compounded versions, their actions are actually leading people to progressively less potentially safe options.